Cell Therapy Developer SBioMedics Raises 2 Billion Won in Paid-in Capital Increase... "For Operating Fund Procurement"
Esbiomedics, a KOSDAQ-listed cell therapy developer, announced on the 13th that it has decided to raise 2 billion KRW through a third-party allotment paid-in capital increase to secure operating funds and other expenses.
A total of 271,320 new common shares will be issued at a price of 25,800 KRW per share. The third-party allotment recipients include SYS Holdings (116,280 shares) and Dongkook Pharmaceutical (58,140 shares), among others.
Hot Picks Today
Karina Fetches 6.7 Billion Won, Lives Under 24-Hour Armed Guard... World's Most Expensive Cow in the Spotlight
- "If It Breaks, That's It": Chaos Among Samsung and SK hynix Consumers... Soaring SSD Prices Mean "No Replacement, Only Refund at Original Price"
- "I'll Pay with Both Shares and Cash" vs "Cash Only"... Why Chey Taewon Filed a Further Appeal After Careful Deliberation
- Another Renaissance Masterpiece Stolen... European Security on High Alert
- Do Night Runners Need Sunscreen? MFDS Says "UV from Streetlights Has Minimal Impact"
The company stated that the purpose of the third-party allotment capital increase is "to achieve management objectives through operating funds and other funds (clinical trial costs)."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
